Association of serum Spp1 levels with disease progression in ALS and SBMA
Annals of Clinical and Translational Neurology · 2024
DOI: 10.1002/acn3.52087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Woohee Ju und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Seoul National University Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Osteopontin, Disease Progression. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Objective
In comparison with amyotrophic lateral sclerosis (ALS), the contribution of neuroinflammation in spinobulbar muscular atrophy (SBMA) has been less explored. We investigated the role of neuroinflammation in the pathogenesis of ALS and SBMA by analyzing systemic inflammatory markers and osteopontin (Spp1).
Methods
This study involved 105 ALS, 77 SBMA, and 55 healthy controls. We measured their systemic inflammatory markers, serum Spp1, and cytokine levels (interferon‐γ, interleukin [IL]‐1β, IL‐6, IL‐8, IL‐10, tumor necrosis factor‐α, and IL‐17A), investigated correlations between Spp1 levels and clinical features, and evaluated ALS survival rates according to Spp1 levels.
Results
In the ALS group, systemic inflammatory markers were significantly higher than in the control and SBMA groups. Spp1 levels were observed to be higher in ALS patients, but the difference was not statistically significant among the study groups. Cytokine profiles were comparable. In ALS, higher Spp1 levels were correlated with lower ALS Functional Rating Scale‐Revised (ALSFRS‐R) scores ( r = −0.25, p = 0.02) and faster disease progression rate ( r = 0.37, p < 0.001). After adjusting for other prognostic indicators, high Spp1 levels were independently associated with shorter survival in ALS patients (hazard ratio 13.65, 95% confidence interval 2.57–72.53, p < 0.01).
Interpretation
Neuroinflammation does not appear to be a primary contributor to the pathogenesis of SBMA. Serum Spp1 levels may serve as a reliable biomarker for disease progression and prognosis in ALS. These findings expand our understanding of these two distinct motor neuron disorders and offer a potential biomarker for future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Neurology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
- Center for Hospital Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
- Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Woohee Ju, Young Gi Min, Yoon-Ho Hong, Seok-Jin Choi, Jung-Joon Sung
Förderung
- National Research Foundation of Korea
Zitieren
APA
Ju, W., Ban, J. J., Im, H. R., Ko, S. H., Seo, J., Min, Y. G., Hong, Y. H., Choi, S. J., & Sung, J. J. (2024). Association of serum Spp1 levels with disease progression in ALS and SBMA. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52087
Vancouver
Ju W, Ban JJ, Im HR, Ko SH, Seo J, Min YG, et al. Association of serum Spp1 levels with disease progression in ALS and SBMA. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52087
BibTeX
@article{Ju2024,
author = {Ju, Woohee and Ban, Jae-Jun and Im, Hye-Ryeong and Ko, Sun Hi and Seo, Jaewoo and Min, Young Gi and Hong, Yoon-Ho and Choi, Seok-Jin and Sung, Jung-Joon},
title = {Association of serum Spp1 levels with disease progression in ALS and SBMA},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
doi = {10.1002/acn3.52087}
}
EUVIMED